Retrospective Analysis: S100 as Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome
Open Access
- 25 February 2025
- journal article
- Published by S. Karger AG in Oncology
- Vol. 103 (10) , 930-933
Abstract
Introduction: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for hematologic malignancies, offering significant therapeutic benefits. However, this therapy is also associated with adverse effects such as cytokine release syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can lead to severe neurological symptoms. The pathophysiology of ICANS remains unclear but is believed to involve immune-mediated inflammation in the brain. This study investigates the potential of S100, a protein marker associated with blood-brain barrier integrity, as an early indicator of ICANS. Methods: We retrospectively analyzed daily blood samples for S100 levels in patients undergoing CAR T-cell therapy, correlating these levels with the onset and severity of ICANS. Results: The results show that S100 levels significantly increased in patients who developed ICANS, with a positive correlation between the duration of elevation and the severity of the neurological symptoms. Conclusion: These findings suggest that S100 may serve as a useful biomarker for early detection of ICANS and could potentially guide therapeutic interventions. However, further studies are needed to fully understand its prognostic value in this context.Keywords
This publication has 11 references indexed in Scilit:
- S100 as marker for immune effector cell-associated neurotoxicity syndromeWiener klinische Wochenschrift, 2024
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaNew England Journal of Medicine, 2023
- Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell TherapyJAMA Neurology, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- S100A6 protein: functional rolesCellular and Molecular Life Sciences, 2017
- Engineering CAR-T cells: Design conceptsTrends in Immunology, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Serum S-100β as a possible marker of blood–brain barrier disruptionBrain Research, 2002